South America Malaria Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Treatment, Drug Type, Route of Administration, Distribution Channel, and End User

List of Tables

The SAM malaria treatment market is expected to grow from US$ 71.79 million in 2022 to US$ 98.53 million by 2028. It is estimated to register a CAGR of 5.4% from 2022 to 2028.

Rapid Diagnostic Tests is Driving the SAM Malaria Treatment Market

RDTs for malaria can improve the quality of management of the disease. RDTs are proven to be highly affordable and effective for public health programs implemented in low-resource settings. RDTs are widely used in remote areas with limited access to microscopy services. As a result, there has been a rapid rise in the demand for RDTs for malaria. Several RDTs have been developed to test the presence of malaria parasites in blood samples. Identifying and successfully treating malaria in low transmission areas is critical to reduce transmission and achieve complete elimination of the disease. Many companies are engaged in developing a wide range of RDTs with high sensitivities. So, growing rapid diagnostic tests is expected to drive the SAM malaria treatment market growth across the region.

SAM Malaria Treatment Market Overview

The SAM malaria treatment market is categorized into Brazil, Argentina, and the Rest of SAM. Brazil held the substantial share in the market during forecast period. Malaria has always been a major public health concern in Brazil. The early history of malaria in Brazil and measures for its control has been powered by the forced relocation of Africans as enslaved people and the colonization of the Europeans. The immigrants brought malaria to different areas of Brazil. In Brazil, malaria is caused by three species of Plasmodium-P. vivax (which accounts for 83.7% of the registered cases), P. falciparum (causing 16.3% of the cases), and P. malariae (a small proportion of cases). The Brazilian government launched the National Malaria Elimination Plan, intending to reduce the number of local malaria cases to less than 68,000 by 2025 and the number of deaths to zero by 2030, as well as eliminate the disease in Brazil by 2035. Brazil is a country that houses the Amazon rainforest, from where most of the malaria cases come. Approximately 99.9% of transmissions in Brazil occur in the Amazon area and 80% in 33 cities.

In 2021, over 137.8 cases were reported. The Brazilian government is investing in treatment, pest control, and technical support to cities and states while also training personnel. The Elimination Plan will work through the Brazilian Unified Health System, based on free diagnosis and treatment, decentralized actions for diagnostic and wide coverage treatment, and using online information systems, multi-sector partnerships, and research networks. On October 30, 2019, GSK Brazil and MMV announced that the Brazilian Health Regulatory Agency (AVINSA) had granted the Marketing Authorization Approval under propriety review for the single dose tafenoquine for the medical cure of plasmodium vivax malaria in 16-year-old patients and for the older who are receiving chloroquine for the acute P. vivax infection. Jose Carlos Felner, the president of the GSK's pharmaceutical division in Brazil, said that the approval of tafenoquine in the country is an important step in the fight against neglected diseases such as malaria. This will increase the demand for malaria treatment in Brazil and help eradicate the disease. Thus, the growing technical support by the Brazilian government can fuel the growth of the market.

SAM Malaria Treatment Market Revenue and Forecast to 2028 (US$ Million)

SAM Malaria Treatment Market Segmentation

The SAM malaria treatment market is segmented based on treatment, drug type, route of administration, distribution channel, end user, and country.

Based on treatment, the SAM malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held the largest market share in 2022. The prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.

Based on drug type, the SAM malaria treatment market is bifurcated into branded and generic. The generic segment held a larger market share in 2022.

Based on route of administration, the SAM malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held a larger market share in 2022.

Based on distribution channel, the SAM malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.

Based on end user, the SAM malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held the largest market share in 2022.

Based on country, the SAM malaria treatment market has been categorized into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that the Rest of SAM dominated the market in 2022.

AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, and Zydus Healthcare Ltd are among the leading companies operating in the SAM malaria treatment market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM malaria treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the SAM malaria treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the malaria treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00027975

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 SAM Malaria Treatment Market - By Treatment
- 1.3.2 SAM Malaria Treatment Market - By Drug Type
- 1.3.3 SAM Malaria Treatment Market - By Route of Administration
- 1.3.4 SAM Malaria Treatment Market - By Distribution Channel
- 1.3.5 SAM Malaria Treatment Market - By End User
- 1.3.6 SAM Malaria Treatment Market- By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. SAM Malaria Treatment Market- Market Landscape

4.1 Overview
4.2 SAM PEST Analysis
4.3 Experts Opinion

5. SAM Malaria Treatment Market - Key Market Dynamics

5.1 Market Drivers.
- 5.1.1 Government and Private Sector's Initiatives to Raise Awareness About Malaria
5.2 Market Restraints
- 5.2.1 Counterfeit Antimalarial Drugs and Subsequent Drug Resistance
5.3 Market Opportunities
- 5.3.1 Extending Pipeline of New Drugs and Vaccines
5.4 Future Trends
- 5.4.1 Rapid Diagnostic Tests
5.5 Impact Analysis

6. Malaria Treatment Market- SAM Analysis

6.1 SAM Malaria Treatment Market Revenue Forecast and Analysis

7. SAM Malaria Treatment Market Analysis - By Treatment

7.1 Overview
7.2 SAM Malaria Treatment Market, By Treatment 2021 & 2028 (%)
7.3 Prescription Medications
- 7.3.1 Overview
- 7.3.2 Prescription Medication Market Revenue and Forecast to 2028 (US$ Mn)
- 7.3.3 Chloroquine Phosphate
  - 7.3.3.1 Overview
  - 7.3.3.2 Chloroquine Phosphate Market Revenue and Forecast to 2028 (US$ Mn)
- 7.3.4 Artemisinin- based Combination Therapies (ACTs)
  - 7.3.4.1 Overview
  - 7.3.4.2 Artemisinin- based Combination Therapies (ACTs) Market Revenue and Forecast to 2028 (US$ Mn)
- 7.3.5 Atovaquone-Proguanil
  - 7.3.5.1 Overview
  - 7.3.5.2 Atovaquone-Proguanil Market Revenue and Forecast to 2028 (US$ Mn)
- 7.3.6 Quinine Sulphate (Qualaquin) with Doxycycline
  - 7.3.6.1 Overview
  - 7.3.6.2 Quinine Sulphate (Qualaquin) with Doxycycline Market Revenue and Forecast to 2028 (US$ Mn)
- 7.3.7 Primaquine Phosphate
  - 7.3.7.1 Overview
  - 7.3.7.2 Primaquine Phosphate Market Revenue and Forecast to 2028 (US$ Mn)
- 7.3.8 Others
  - 7.3.8.1 Overview
  - 7.3.8.2 Others Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Vaccines
- 7.4.1 Overview
- 7.4.2 Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Diagnostic Tests
- 7.5.1 Overview
- 7.5.2 Diagnostic Tests Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others Market Revenue and Forecast to 2028 (US$ Mn)

8. SAM Malaria Treatment Market Analysis - By Drug Type

8.1 Overview
8.2 SAM Malaria Treatment Market, By Drug Type 2021 & 2028 (%)
8.3 Branded
- 8.3.1 Overview
- 8.3.2 Branded Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Generics
- 8.4.1 Overview
- 8.4.2 Generics Market Revenue and Forecast to 2028 (US$ Mn)

9. SAM Malaria Treatment Market Analysis - By Route of Administration

9.1 Overview
9.2 SAM Malaria Treatment Market, By Route of Administration 2021 & 2028 (%)
9.3 Oral
- 9.3.1 Overview
- 9.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Parenteral and Intravenous Mode
- 9.4.1 Overview
- 9.4.2 Parenteral and Intravenous Mode Market Revenue and Forecast to 2028 (US$ Mn)

10. SAM Malaria Treatment Market Analysis - By Distribution Channel

10.1 Overview
10.2 SAM Malaria Treatment Market, By Distribution Channel 2021 & 2028 (%)
10.3 Direct Tender
- 10.3.1 Overview
- 10.3.2 Direct Tender Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Hospital Pharmacies
- 10.4.1 Overview
- 10.4.2 Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Mn)
10.5 Retail Pharmacies
- 10.5.1 Overview
- 10.5.2 Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Mn)
10.6 Online Pharmacies
- 10.6.1 Overview
- 10.6.2 Online Pharmacies Market Revenue and Forecast to 2028 (US$ Mn)
10.7 Others
- 10.7.1 Overview
- 10.7.2 Others Market Revenue and Forecast to 2028 (US$ Mn)

11. SAM Malaria Treatment Market Analysis - By End User

11.1 Overview
11.2 SAM Malaria Treatment Market, By End User 2021 & 2028 (%)
11.3 Hospitals
- 11.3.1 Overview
- 11.3.2 Hospitals Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Specialty Clinics
- 11.4.1 Overview
- 11.4.2 Specialty Clinics Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare
- 11.5.1 Overview
- 11.5.2 Homecare Market Revenue and Forecast to 2028 (US$ Mn)
11.6 Others
- 11.6.1 Overview
- 11.6.2 Others Market Revenue and Forecast to 2028 (US$ Mn)

12. SAM Malaria Treatment Market - Country Analysis

12.1 Overview
- 12.1.1 SAM: Malaria Treatment Market, by Country, 2021 & 2028 (%)
  - 12.1.1.1 Brazil: Malaria Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    - 12.1.1.1.1 Brazil: Malaria Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    - 12.1.1.1.2 Brazil: Malaria Treatment Market, by Treatment, 2019 - 2028 (US$ Million)
    - 12.1.1.1.2.1 Brazil: Malaria Treatment Market, by Prescription medications, 2019 - 2028 (US$ Million)
    - 12.1.1.1.3 Brazil: Malaria Treatment Market, by Drug Type, 2019 - 2028 (US$ Million)
    - 12.1.1.1.4 Brazil: Malaria Treatment Market, by Route of Administration, 2019 - 2028 (US$ Million)
    - 12.1.1.1.5 Brazil: Malaria Treatment Market, by Distribution Channel, 2019 - 2028 (US$ Million)
    - 12.1.1.1.6 Brazil: Malaria Treatment Market, by End User, 2019 - 2028 (US$ Million)
  - 12.1.1.2 Argentina: Malaria Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    - 12.1.1.2.1 Argentina: Malaria Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    - 12.1.1.2.2 Argentina: Malaria Treatment Market, by Treatment, 2019 - 2028 (US$ Million)
    - 12.1.1.2.2.1 Argentina: Malaria Treatment Market, by Prescription Medications, 2019 - 2028 (US$ Million)
    - 12.1.1.2.3 Argentina: Malaria Treatment Market, by Drug Type, 2019 - 2028 (US$ Million)
    - 12.1.1.2.4 Argentina: Malaria Treatment Market, by Route of Administration, 2019 - 2028 (US$ Million)
    - 12.1.1.2.5 Argentina: Malaria Treatment Market, by Distribution Channel, 2019 - 2028 (US$ Million)
    - 12.1.1.2.6 Argentina: Malaria Treatment Market, by End User, 2019 - 2028 (US$ Million)
  - 12.1.1.3 Rest of SAM: Malaria Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    - 12.1.1.3.1 Rest of SAM: Malaria Treatment Market Revenue and Forecasts to 2028 (US$ Million)
    - 12.1.1.3.2 Rest of SAM: Malaria Treatment Market, by Treatment, 2019 - 2028 (US$ Million)
    - 12.1.1.3.2.1 Rest of SAM: Malaria Treatment Market, by Prescription Medications, 2019 - 2028 (US$ Million)
    - 12.1.1.3.3 Rest of SAM: Malaria Treatment Market, by Drug Type, 2019 - 2028 (US$ Million)
    - 12.1.1.3.4 Rest of SAM: Malaria Treatment Market, by Route of Administration, 2019 - 2028 (US$ Million)
    - 12.1.1.3.5 Rest of SAM: Malaria Treatment Market, by Distribution Channel, 2019 - 2028 (US$ Million)
    - 12.1.1.3.6 Rest of SAM: Malaria Treatment Market, by End User, 2019 - 2028 (US$ Million)

13. Industry Landscape

13.1 Overview
13.2 Inorganic Growth Strategies
- 13.2.1 Overview
13.3 Organic Growth Strategies
- 13.3.1 Overview

14. Company Profiles

14.1 Zydus Healthcare Ltd
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Sun Pharmaceutical Industries Ltd
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 GSK Plc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Novartis AG
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Cipla Ltd
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Viatris Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Lupin Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 AdvaCare Pharma USA LLC
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms